Loading...
Please wait, while we are loading the content...
Similar Documents
Treatment Failure of TNF-α Inhibitors in Obese Patients With Inflammatory Bowel Disease-A Cohort Study.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Madsen, Kenneth Grønkjær Pottegård, Anton Hallas, Jesper Kjeldsen, Jens E. |
| Copyright Year | 2018 |
| Abstract | Background In treatment of inflammatory bowel disease (IBD) with anti-tumor necrosis factor-α agents (anti-TNF-α), obesity has been suspected as a cause of accelerated loss of response (LOR). We sought to determine whether overweight IBD patients have accelerated LOR when treated with anti-TNF-α agents, compared with normal weight IBD patients. Methods We identified a cohort of adult IBD patients treated with anti-TNF-α agents at a Danish university hospital. Patients were grouped according to body mass index (BMI), and our main outcome was time to LOR. We performed survival analyses on LOR and calculated hazard ratios (HRs) with the normal weight group as the reference, while adjusting for confounders. Results Of 210 eligible patients, 92 (44%) experienced LOR. One hundred eighty patients were treated with infliximab and 30 with adalimumab, 114 (54%) were normal weight, 51 (24%) were overweight, and 45 (21%) were obese. Regression analysis produced the following adjusted HRs, compared with the normal weight group: overweight 0.89 (95% confidence interval [CI], 0.51-1.56) and obese 1.31 (95% CI, 0.76-2.24), thus showing no statistically significant association between BMI and time to LOR. Subgroup analyses produced similar results, except for obese ulcerative colitis patients having an adjusted HR of 2.42 (95% CI, 1.03-5.70). Conclusions In IBD patients treated with anti-TNF-α agents, we found no overall association between increased BMI and accelerated LOR. |
| Starting Page | 2628 |
| Ending Page | 2633 |
| Page Count | 6 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://www.antonpottegaard.dk/publications/originalarticles/133.pdf |
| PubMed reference number | 29788214v1 |
| Alternate Webpage(s) | https://doi.org/10.1093/ibd/izy178 |
| DOI | 10.1093/ibd/izy178 |
| Journal | Inflammatory bowel diseases |
| Volume Number | 24 |
| Issue Number | 12 |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Body Dysmorphic Disorders Confidence Intervals Eighty Inflammatory Bowel Diseases Intestinal Diseases Intestines Irritable Bowel Syndrome LOR gene Neoplasms Obesity Overweight Patients Ulcer Ulcerative Colitis adalimumab infliximab tumor necrosis |
| Content Type | Text |
| Resource Type | Article |
